An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19

Rationale: Coronavirus disease 2019 (COVID-19) can cause disruption of the renin-angiotensin system in the lungs, possibly contributing to pulmonary capillary leakage. Thus, angiotensin receptor blockers (ARBs) may improve respiratory failure. Objective: Assess safety of losartan for use in respirat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bengtson, Charles D., Montgomery, Robert N., Nazir, Usman, Satterwhite, Lewis, Kim, Michael D., Bahr, Nathan C., Castro, Mario, Baumlin, Nathalie, Salathe, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926174/
https://www.ncbi.nlm.nih.gov/pubmed/33681257
http://dx.doi.org/10.3389/fmed.2021.630209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926174/
https://www.ncbi.nlm.nih.gov/pubmed/33681257
http://dx.doi.org/10.3389/fmed.2021.630209

Ejemplares similares